Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 21:32 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Efficiency of Antagonist Drugs of the Cellular Transcriptomic Signature of Influenza A Virus Infection.
NCT03212716 · University Hospital, Lille · PHASE2 · terminated · last registry update 2023-02-06 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “rate of inclusion and study affected by covid-19 epidemic” | – | Registry record, University Hospital, Lille |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CACNA1C within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-11-27Results posted on the registry: BeiGene, Zanubrutinib + Fluconazole (NCT04551963)
- 2023-10-12Results posted on the registry: University of Cincinnati, Nicardipine + Labetalol (NCT04116112)
- 2023-07-18Also stopped (terminated): Seoul National University Hospital, Amiodarone, diltiazem or esmolol (NCT05950971)
- 2023-07-11Phase 3 first posted: Region Örebro County, dronedarone - Multaq™ OR flecainide - Tambocor™ OR propafenone - Rytmonorm™ OR sotalol - Sotacor™ (NCT05939076)
- 2023-05-26Also stopped (withdrawn): Hospices Civils de Lyon, DILTIAZEM TEVA 60 mg or placebo (NCT05563168)
- 2023-03-01Results posted on the registry: Virginia Commonwealth University, Diltiazem Oral Product + Diltiazem Injectable Product (NCT03472495)
- 2022-07-27Also stopped (withdrawn): EMS, LENINGRADO association + Indapamide SR 1.5 MG (NCT03814109)
- 2022-03-24Phase 3 first posted: Universitätsklinikum Hamburg-Eppendorf, a drug against CACNA1C (NCT05293080)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision